[by Ji, Yong Jun] Peptron announced on June 4 that the technology evaluation contract for the 에볼루션 바카라 사이트 of the long-acting obesity treatment, 'SmartDepot,' in collaboration with Eli Lilly in the United States, is progressing smoothly.Peptron recently provided this clarification following Eli Lilly
[by Ji, Yong Jun] ABL Bio announced on June 4 that it has received approval from the Ministry of Food and Drug Safety for the clinical phase 1b/2 trial (IND) plan. The trial will evaluate the triple combination therapy of ABL Bio’s dual antibody candidate, 'ABL103 (에볼루션 바카라 사이트 code),' MSD (Merck, US
[by Kang, In Hyo] Tiumbio announced on June 4 that it has revealed partial clinical data from the phase 2 clinical trial evaluating the combination therapy of ‘TU2218 (에볼루션 바카라 사이트 code)’ and ‘Keytruda,’ currently under 에볼루션 바카라 사이트.The clinical trial was designed to verify the potential synergistic e
[by Ji, Yong Jun] D&D Pharmatech announced on June 4 that it completed the 'Database Lock' on May 21, a step that finalizes clinical information and figures in preparation for analyzing the primary evaluation index results of the Phase 2 clinical trial of 'DD01 (에볼루션 바카라 사이트 code),' a candidate treat
[by Sung, Jae Jun] ACRYL, an AI infrastructure technology company, announced on June 5 its participation in 'Smart Tech Korea 2025 – AI & Big Data Show', to be held at COEX in Seoul from June 11 to 13. At the exhibition, ACRYL will present its flagship AI platform Jonathan and healthcare-specialized
[by Lee, Young Sung] Avelos Therapeutics (hereinafter referred to as Avelos), a biotechnology firm specializing in the 에볼루션 바카라 사이트 of anticancer drugs, has disclosed preclinical data on two assets targeting the DNA damage response (DDR) field, expressing confidence in the potential for future techno
[by Lee, Young Sung] Verismo Therapeutics, a U.S. subsidiary of HLB Group, has announced its objective of commercializing 'SynKIR-110' as a 'first-in-class' treatment for solid tumors. SynKIR-110 is a next-generation CAR-T (chimeric antigen receptor T cell) therapy developed using the company's prop
[by Yu, Suin] Humedix of Huons Group will host an academic gathering to showcase its product competitiveness.Humedix Co., Ltd. announced on June 4 that it has begun recruiting participants for its upcoming HART Symposium, which will focus on case studies in the field of aesthetics. The event is sche
[더에볼루션 바카라 사이트 이영성 기자] 항암신약개발 전문 에볼루션 바카라 사이트텍인 아벨로스테라퓨틱스(이하 아벨로스)가 DNA 손상 반응(DNA damage response. 이하 DDR) 분야에서 두 가지 에셋(Asset)에 대한 비임상 데이터들을 공개하며, 향후 기술이전에 대한 자신감을 내비쳤다. 해당 신약 후보물질들이 기존 항암제와의 병용요법으로 경쟁약보다 항암효과를 크게 끌어올린 데이터를 토대로, 앞으로 임상시험을 거치면서 에셋의 가치를 눈덩이처럼 키우겠다는 각오다. 아벨로스는 DDR을 비롯해 합성치사(Synthetic Lethality), 세포주기(Ce
[by Kang, In Hyo] “We initially began as a consulting firm specializing in pharmaceutical and biotech strategies and subsequently expanded our scope to function as an accelerator (AC) focused on identifying and nurturing biotech startups. Now, we intend to fully support the growth of promising Korea
[by Lee, Young Sung] AstraZeneca (AZ) has projected that within the next decade, achieving a 'cure for cancer' will become possible. Historically, chemotherapy was the sole treatment option for cancer, however, emerging options such as antibody-drug conjugates (ADCs) and bispecific antibodies are ex
[더에볼루션 바카라 사이트 강인효 기자] “제약에볼루션 바카라 사이트 전문 전략자문사로 출발해 에볼루션 바카라 사이트 스타트업을 발굴·육성하는 액셀러레이터(AC)로 사업 영역을 넓혀왔습니다. 이제는 직접적인 자본 투자(Capital Play)를 통해 국내 유망 에볼루션 바카라 사이트·헬스케어 기업의 성장을 본격적으로 지원할 계획입니다.”미리어드파트너스 창업자인 성상용 대표는 최근 와 인터뷰에서 이같이 말했다. 미리어드파트너스는 지난 4월 말 ‘2025년 모태펀드 1차 정시 출자 사업’ 창업 초기 소형 분야의 최종 위탁운용사(GP)로 선정됐다. 성 대표는 “이번 GP 선정은 미리어드파트
[by Yu, Suin] The Korea Drug 에볼루션 바카라 사이트 Fund (KDDF) announced on May 29 that the ‘2025 KDDF Global Biotech Showcase,’ held from May 27 to 28 at the Fairmont Ambassador Seoul, concluded successfully, marking a record turnout with the highest number of participating investors to date.This event was o
[by Ji, Yong Jun] Idience, a 에볼루션 바카라 사이트 drug development subsidiary of the Ildong Pharmaceutical Group, announced on May 29 that it will present clinical research findings on the combination therapy of its PARP inhibitor anticancer drug candidate, 'venadaparib,' at the upcoming 2025 American Society of Cli
[by Kang, In Hyo] Dr. Noah Biotech, a company specializing in AI-based 에볼루션 바카라 사이트 drug development, announced on May 30 that it has been officially selected for the 2025 Global Enterprise Collaboration Program, ‘Daonda,’ organized by the Korea Institute of Startup & Entrepreneurship Development (KISED) und
[by Sung, Jae Jun] Kangstem Biotech announced on May 29 that its knee osteoarthritis treatment candidate, 'OSCA', demonstrates improved therapeutic effects lasting 12 months with a single injection in the Phase 1 clinical trial. Based on these results, the company stated that the possibility of succ
[by Kang, In Hyo] Nelmastobart, a next-generation immuno-oncology drug and anti-BTN1A1 immune checkpoint inhibitor under 에볼루션 바카라 사이트, represents a genuine first-in-class novel drug candidate. By targeting ‘BTN1A1,’ a unique biomarker differentiated from ‘PD-L1,’ which is currently used to predict im
[더에볼루션 바카라 사이트 강인효 기자] “우리가 개발하고 있는 항BTN1A1 면역관문억제제이자 차세대 면역항암제인 ‘넬마스토바트(Nelmastobart)’는 진정한 계열 내 최초(first-in-class) 신약 후보물질입니다. 넬마스토바트는 면역항암 반응을 예측할 수 있는 대표적인 에볼루션 바카라 사이트마커인 ‘PD-L1’과는 차별화되는 독자적인 에볼루션 바카라 사이트마커인 ‘BTN1A1’을 타깃하기 때문에 기존 면역관문억제제로 치료가 되지 않는 암환자들의 미충족 수요를 해결할 수 있을 것으로 기대하고 있습니다.”유승한 에스티큐브 최고과학책임자(CSO) 겸 에스티큐브파마슈티컬
[by Kang, In Hyo] ILDONG Bioscience, a health functional food subsidiary of the Ildong Pharmaceutical Group, announced on May 27 its participation in the ‘2025 Vitafoods Europe.’ The company aims to showcase its portfolio of functional ingredients and actively pursue opportunities to strengthen its
[by Sung, Jae Jun] Novartis Korea announced on May 27 that it hosted a luncheon symposium highlighting the clinical value of 'COSENTYX (secukinumab)' during the 45th Korean College of Rheumatology Annual Scientific Meeting & the 19th International Symposium (KCR 2025), held on May 16. The symposium
